Loading...
XSHE002900
Market cap399mUSD
Jan 09, Last price  
9.47CNY
1D
-1.87%
1Q
4.41%
IPO
-50.37%
Name

Harbin Medisan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002900 chart
P/E
39.81
P/S
2.47
EPS
0.24
Div Yield, %
1.40%
Shrs. gr., 5y
-0.62%
Rev. gr., 5y
-11.39%
Revenues
1.19b
+15.40%
491,169,900601,230,216681,521,376722,016,528760,872,1001,148,830,3172,172,516,4382,102,061,1891,338,882,990945,799,4221,028,413,6171,186,786,001
Net income
74m
+143.86%
82,717,056104,393,794146,983,581166,301,367175,182,785181,075,538205,813,379177,184,36829,324,801350,951,06430,207,31173,663,110
CFO
36m
-75.32%
123,217,922167,098,700116,310,824200,849,961231,183,499223,458,300292,457,733320,140,78600144,641,85335,693,579
Dividend
Jun 05, 20240.2 CNY/sh
Earnings
May 16, 2025

Profile

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical pharmaceutical dosage forms and APIs in China. It offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, body fluid balance infusion, and other medical fields. The company was founded in 1996 and is based in Harbin, China.
URL
http://www.medisan.com.cn/
IPO date
Sep 22, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,186,786
15.40%
1,028,414
8.73%
Cost of revenue
1,047,654
934,607
Unusual Expense (Income)
NOPBT
139,132
93,807
NOPBT Margin
11.72%
9.12%
Operating Taxes
11,295
13,567
Tax Rate
8.12%
14.46%
NOPAT
127,837
80,240
Net income
73,663
143.86%
30,207
-91.39%
Dividends
(41,037)
(99,131)
Dividend yield
0.98%
2.29%
Proceeds from repurchase of equity
(1,170)
47,291
BB yield
0.03%
-1.09%
Debt
Debt current
275,267
233,796
Long-term debt
246,493
428,075
Deferred revenue
79,028
83,865
Other long-term liabilities
2
1
Net debt
(1,178,390)
(1,187,642)
Cash flow
Cash from operating activities
35,694
144,642
CAPEX
(299,579)
Cash from investing activities
(260,523)
419,253
Cash from financing activities
(15,082)
FCF
(71,300)
177,006
Balance
Cash
1,048,916
1,293,899
Long term investments
651,234
555,614
Excess cash
1,640,811
1,798,092
Stockholders' equity
937,055
1,061,087
Invested Capital
1,803,623
1,719,338
ROIC
7.26%
4.84%
ROCE
4.84%
3.23%
EV
Common stock shares outstanding
306,930
316,600
Price
13.65
0.00%
13.65
-34.47%
Market cap
4,189,589
-3.05%
4,321,591
-33.03%
EV
3,018,931
3,145,265
EBITDA
253,157
200,375
EV/EBITDA
11.93
15.70
Interest
22,890
22,621
Interest/NOPBT
16.45%
24.11%